We help leading pharmaceutical and biotech companies navigate and resolve contentious issues arising out of their life sciences contracts, especially those involving highly technical, IP-rich subject matter.

Our team has in-depth knowledge of the drug development life cycle from bench-scale production through to trial phases, regulatory approval, manufacture scale-up and commercialisation. This informed expertise means we are able to resolve a wide spectrum of disputes such as those relating to licensing IP and know-how, technical/quality agreements, research collaboration contracts, API manufacturing, development services, supply and distribution.

We also advise on product liability and misuse of confidential information matters related to medicinal drugs and medical devices.

Our clients trust us to assess and manage complex disputes through to resolution on a spread of issues including breach of contract, wrongful termination, royalty rate assessments, trial phases, GMP and regulatory compliance, product liability and misuse of confidential information. Where needed, we bring in expertise from our specialist life sciences regulatory, patent litigation and commercial contracts teams.

If unavoidable, we vigorously deploy our strong experience in litigation, arbitration and other forms of ADR such as mediation, expert determination and judicial review to protect our clients’ interests and enforce their rights.

Key contact

Mark Brown

Contact

Experience

Licence fees and royalty rate dispute of a pharma product: Representing a pharma company in relation to a claim for royalties under a collaboration agreement for the development of a monoclonal antibody blockbuster drug.

Wrongful termination and breaches of pharma product manufacture and supply contracts: Representing a pharma company in relation to the contested termination of manufacture and supply contracts of a licensed active pharmaceutical ingredient.

Breaches of technical quality contracts and regulatory compliance: Representing a pharma company in relation to claims against CMO for breaches of technical quality agreement, GMP guidelines and CAPAs concerning OOS API batches.

Breach of reasonable endeavours obligations under licence agreement: Advising a pharma company in a claim relating to breaches of a licence, development and commercialisation agreement for failure to comply with “reasonable endeavours” obligations to promote and sell a peptide drug.

Master Services Agreement for human drug trials: Advising a biotech client in relation to breaches of work orders under a master services agreement for the conduct of clinical trials.

Misuse of confidential information: Representing a pharma company in relation to allegations of misuse of confidential information relating to the formula of an active pharmaceutical ingredient.

Latest articles

What others say

“Strong UK-based practice offering expertise in pan-European IP matters, with a solid reputation in cross-border matters of both a transactional and contentious nature.”

Chambers and Partners Europe 2021

“You are confident you will get really sound advice from them.”

Chambers and Partners Europe 2021

“Excellent advice on UK and European regulatory frameworks.”

Chambers and Partners Global 2021

“A leading destination for advice with regard to digital health and medtech.”

Chambers and Partners Global 2021

“Responsive, flexible, efficient, cost-effective and creative.”

Chambers and Partners 2021

“They are real specialists in this field and are extremely hard-working.”

Chambers and Partners 2021

“Noted for particular strength in IP litigation and the licensing of telecoms SEPs.”

Chambers and Partners 2021

“Bristows’ lawyers are ‘brilliant at communicating and very good team players’.”

Chambers and Partners 2021

“Very client-focused and good on quality.”

Chambers and Partners 2021

“An excellent firm”

Chambers and Partners 2021

“Commentators describe the team members as ‘extremely competent and very pragmatic’.”

Chambers and Partners 2021

“Superb technology law and commercial advice to customers and suppliers of IT and business process services.”

Chambers and Partners 2021

“A leading destination for advice with regard to digital health and medtech, and associated data privacy issues.”

Chambers and Partners 2021

“Excellent advice on UK and European regulatory frameworks and also commercial and corporate transactions for emerging innovators as well as giants of the life sciences industry.”

Chambers and Partners 2021

“Superb patent litigation and IP practice.”

Chambers and Partners 2021

Recent rankings and awards

Life Sciences - Band 1
Chambers and Partners UK 2021

Life Sciences: Transactional - Band 2
Chambers and Partners UK 2021

Life Sciences and Healthcare - Tier 1
Legal 500 2021

Commercial Litigation
Leaders League UK 2020